Prosecution Insights
Prosecution Insights
13 pending office actions • 8 art units • 12 examiners • 0 of 13 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (23%) |
| Double-patenting + other | 5 (38%) |
| Multi-statute (no §101) | 5 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WESTERBERG, NISSA M | 2 | 23.3% | +36.8% |
| MOORE, SUSANNA | 1 | 67.9% | +31.6% |
| WHITEMAN, BRIAN A | 1 | 68.4% | +16.7% |
| BAUER, BRIANNA LEE | 1 | — | — |
| SKELDING, ZACHARY S | 1 | 59.8% | +41.0% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| CHEONG, CHEOM-GIL | 1 | 64.0% | +51.7% |
| OH, TAYLOR V | 1 | 81.2% | +15.3% |
| CARTER, SANDRA DILLAHUNT | 1 | 56.1% | +29.7% |
| GODDARD, LAURA B | 1 | 51.0% | +14.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17783591 | ANTISENSE GUIDE RNA WITH ADDED FUNCTIONAL REGION FOR EDITING TARGET RNA | TRAN, CHRISTINA L | 117d overdue |
| 17632157 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 AND IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF CANCER | NATARAJAN, MEERA | 31d overdue |
| 18279103 | Methods of Reducing Risk of Prostate Cancer Progression | OH, TAYLOR V | 17d overdue |
| 18723117 | SUBSTITUTED QUINOLINE DERIVATIVE | MOORE, SUSANNA | — |
| 18710652 | INDOCYANINE COMPOUND-CONTAINING SOLID PHARMACEUTICAL COMPOSITION | WESTERBERG, NISSA M | — |
| 18291487 | A PHARMACEUTICAL COMPOSITION FOR IMAGING | WESTERBERG, NISSA M | — |
| 18269531 | GUIDE RNA FOR EDITING POLYADENYLATION SIGNAL SEQUENCE OF TARGET RNA | WHITEMAN, BRIAN A | — |
| 18246418 | PHARMACEUTICAL COMPOSITION FOR OTIC ADMINISTRATION | CARTER, SANDRA DILLAHUNT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18279103 | Methods of Reducing Risk of Prostate Cancer Progression | OH, TAYLOR V | 17d overdue |
| 18723117 | SUBSTITUTED QUINOLINE DERIVATIVE | MOORE, SUSANNA | — |
| 18710652 | INDOCYANINE COMPOUND-CONTAINING SOLID PHARMACEUTICAL COMPOSITION | WESTERBERG, NISSA M | — |
| 18291487 | A PHARMACEUTICAL COMPOSITION FOR IMAGING | WESTERBERG, NISSA M | — |
| 18269531 | GUIDE RNA FOR EDITING POLYADENYLATION SIGNAL SEQUENCE OF TARGET RNA | WHITEMAN, BRIAN A | — |
| 18552113 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | SKELDING, ZACHARY S | — |
| 18283634 | Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer | O DELL, DAVID K | — |
| 18468103 | BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN6 OR CLAUDIN18.2 AND CD3 FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | CHEONG, CHEOM-GIL | — |
| Art Unit | Apps |
|---|---|
| 1674 | 2 |
| 1623 | 1 |
| 1621 | 1 |
| 1645 | 1 |
| 1625 | 1 |
| 1642 | 1 |
| 1637 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18723117 | SUBSTITUTED QUINOLINE DERIVATIVE | MOORE, SUSANNA | — | §101§112 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18710652 | INDOCYANINE COMPOUND-CONTAINING SOLID PHARMACEUTICAL COMPOSITION | WESTERBERG, NISSA M | — | §103§112 | Non-Final OA | — | Pending | May 16, 2024 |
| 18291487 | A PHARMACEUTICAL COMPOSITION FOR IMAGING | WESTERBERG, NISSA M | — | §103DP | Non-Final OA | — | Pending | Jan 23, 2024 |
| 18269531 | GUIDE RNA FOR EDITING POLYADENYLATION SIGNAL SEQUENCE OF TARGET RNA | WHITEMAN, BRIAN A | — | §101§102§103§112DP | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18566516 | METHODS OF USE OF PPAR AGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | BAUER, BRIANNA LEE | 1623 | §103§112DP | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18552113 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | SKELDING, ZACHARY S | 1674 | §102§112DP | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18283634 | Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer | O DELL, DAVID K | 1621 | §102§103§112DP | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18468103 | BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN6 OR CLAUDIN18.2 AND CD3 FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | CHEONG, CHEOM-GIL | 1645 | §103DP | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18279103 | Methods of Reducing Risk of Prostate Cancer Progression | OH, TAYLOR V | 1625 | §102§103§112 | Final Rejection | 17d overdue | Pending | Aug 28, 2023 |
| 18246418 | PHARMACEUTICAL COMPOSITION FOR OTIC ADMINISTRATION | CARTER, SANDRA DILLAHUNT | 1674 | §102§103§112 | Non-Final OA | — | Pending | Mar 23, 2023 |
| 18021581 | HUMAN NON-NATURALLY OCCURRING MODIFIED FC REGION OF IGG SPECIFICALLY BINDING TO NON-NATURALLY OCCURRING MODIFIED FC RECEPTOR | GODDARD, LAURA B | 1642 | §102§112 | Non-Final OA | — | Pending | Feb 16, 2023 |
| 17783591 | ANTISENSE GUIDE RNA WITH ADDED FUNCTIONAL REGION FOR EDITING TARGET RNA | TRAN, CHRISTINA L | 1637 | §101§102§103 | Non-Final OA | 117d overdue | Pending | Jun 08, 2022 |
| 17632157 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 AND IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF CANCER | NATARAJAN, MEERA | 1643 | §102§103§112 | Non-Final OA | 31d overdue | Pending | Feb 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial